Pacer Advisors
IOVA icon

Pacer Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

Pacer Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28K Buy
+6,729
New +$25.6K ﹤0.01% 2183
2024
Q3 		– Sell
-3,831
Closed -$30.7K – 2623
2024
Q2 		$30.7K Buy
3,831
+1,115
+41% +$11.9K ﹤0.01% 3332
2024
Q1 		$40.3K Buy
+2,716
New +$31.6K ﹤0.01% 3258
2021
Q2 		– Sell
-2,187
Closed -$69K – 1477
2021
Q1 		$69K Sell
2,187
-458
-17% -$19K ﹤0.01% 1382
2020
Q4 		$123K Sell
2,645
-916
-26% -$36.4K ﹤0.01% 1332
2020
Q3 		$117K Buy
+3,561
New +$109K ﹤0.01% 1236
2018
Q4 		– Sell
-8,666
Closed -$97K – 789
2018
Q3 		$97K Buy
+8,666
New +$123K ﹤0.01% 1096

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Pacer Advisors's IOVA Position: Q2 2026 in Review

Pacer Advisors opened a new position in Iovance Biotherapeutics (IOVA) in Q2 2026: 6,729 shares worth $28K. The stake represents ﹤0.01% of the portfolio and ranks #2183 among its holdings. This is a return to the name: Pacer Advisors previously reported a position in IOVA as recently as Q2 2024.

Pacer Advisors first reported a position in IOVA in Q3 2018 and has held it in 7 quarters since. The position peaked at $123K in Q4 2020. 293 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Pacer Advisors held 6,729 shares of Iovance Biotherapeutics worth $28K as of Q2 2026.
  • Iovance Biotherapeutics was a new Pacer Advisors position in Q2 2026.
  • Iovance Biotherapeutics made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #2183 holding.
  • Pacer Advisors first reported a position in Iovance Biotherapeutics in Q3 2018 and has held it in 7 quarters since.
  • Pacer Advisors's Iovance Biotherapeutics position peaked at $123K in Q4 2020.
  • 293 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.